ADC Gross Profit from 2010 to 2025

ADCT Stock

USD 1.62 0.01 0.62%

ADC Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit ADC Therapeutics SA makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2018-03-31

Previous Quarter

15.4 M

Current Value

17.6 M

Quarterly Volatility

28.1 M

Covid

Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 2.7 M or Interest Expense of 55.9 M, as well as many indicators such as Price To Sales Ratio of 2.13, Dividend Yield of 0.0 or Days Sales Outstanding of 228. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.

Check out the analysis of ADC Therapeutics Correlation against competitors.

Latest ADC Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of ADC Therapeutics SA over the last few years. Gross profit is a required income statement account that reflects total revenue of ADC Therapeutics SA minus its cost of goods sold. It is profit before ADC Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. ADC Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADC Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (59.85 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

ADC Gross Profit Regression Statistics

	Arithmetic Mean	23,206,117
	Geometric Mean	7,357,631
	Coefficient Of Variation	278.57
	Mean Deviation	43,359,036
	Median	1,803,000
	Standard Deviation	64,645,001
	Sample Variance	4179T
	Range	310.5M
	R-Value	0.50
	Mean Square Error	3371.3T
	R-Squared	0.25
	Significance	0.05
	Slope	6,749,105
	Total Sum of Squares	62684.6T

ADC Gross Profit History

	2025	80.9 M
	2024	77.1 M
	2023	67 M
	2022	205.3 M
	2021	32.5 M
	2020	-2 M
	2019	-105.2 M

Other Fundumenentals of ADC Therapeutics

Gross Profit Margin

ADC Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Short Term Debt	Long Term Debt	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab
Total Assets		-0.11	0.52	-0.74	-0.79	0.73	0.68	0.78	1.0	0.83	0.83	-0.34	-0.24	0.0	0.86	0.8	0.83	0.7	0.04	-0.45	0.61	0.49
Total Stockholder Equity	-0.11		-0.77	-0.52	0.65	-0.62	-0.39	-0.7	-0.15	-0.5	-0.46	0.8	0.65	0.94	0.06	-0.54	-0.5	0.32	0.41	0.9	-0.76	-0.81
Current Deferred Revenue	0.52	-0.77		0.07	-0.73	0.78	0.69	0.85	0.54	0.63	0.53	-0.74	-0.61	-0.67	0.38	0.68	0.57	0.03	-0.28	-0.82	0.82	0.78
Net Debt	-0.74	-0.52	0.07		0.25	-0.23	-0.15	-0.21	-0.73	-0.35	-0.38	-0.29	-0.17	-0.57	-0.76	-0.29	-0.36	-0.86	-0.39	-0.15	0.03	0.15
Retained Earnings	-0.79	0.65	-0.73	0.25		-0.91	-0.7	-0.96	-0.8	-0.95	-0.94	0.76	0.51	0.58	-0.5	-0.93	-0.95	-0.3	0.23	0.86	-0.89	-0.84
Accounts Payable	0.73	-0.62	0.78	-0.23	-0.91		0.68	0.88	0.76	0.93	0.84	-0.74	-0.37	-0.59	0.43	0.89	0.84	0.24	-0.08	-0.8	0.91	0.85
Net Receivables	0.68	-0.39	0.69	-0.15	-0.7	0.68		0.71	0.67	0.71	0.68	-0.61	-0.17	-0.27	0.5	0.74	0.68	0.13	-0.25	-0.49	0.8	0.71
Total Liab	0.78	-0.7	0.85	-0.21	-0.96	0.88	0.71		0.8	0.88	0.86	-0.73	-0.64	-0.59	0.58	0.89	0.89	0.29	-0.28	-0.89	0.88	0.84
Total Current Assets	1.0	-0.15	0.54	-0.73	-0.8	0.76	0.67	0.8		0.84	0.84	-0.34	-0.26	-0.03	0.86	0.81	0.84	0.68	0.03	-0.49	0.63	0.52
Intangible Assets	0.83	-0.5	0.63	-0.35	-0.95	0.93	0.71	0.88	0.84		0.97	-0.72	-0.33	-0.47	0.49	0.97	0.96	0.39	-0.07	-0.72	0.86	0.78
Common Stock	0.83	-0.46	0.53	-0.38	-0.94	0.84	0.68	0.86	0.84	0.97		-0.62	-0.32	-0.38	0.56	0.96	0.99	0.42	-0.09	-0.69	0.82	0.75
Net Tangible Assets	-0.34	0.8	-0.74	-0.29	0.76	-0.74	-0.61	-0.73	-0.34	-0.72	-0.62		0.5	0.86	0.07	-0.74	-0.65	0.13	0.33	0.75	-0.76	-0.75
Capital Surpluse	-0.24	0.65	-0.61	-0.17	0.51	-0.37	-0.17	-0.64	-0.26	-0.33	-0.32	0.5		0.62	-0.17	-0.32	-0.41	0.11	0.7	0.72	-0.43	-0.54
Net Invested Capital	0.0	0.94	-0.67	-0.57	0.58	-0.59	-0.27	-0.59	-0.03	-0.47	-0.38	0.86	0.62		0.29	-0.47	-0.42	0.43	0.43	0.83	-0.67	-0.73
Net Working Capital	0.86	0.06	0.38	-0.76	-0.5	0.43	0.5	0.58	0.86	0.49	0.56	0.07	-0.17	0.29		0.51	0.56	0.73	0.13	-0.26	0.37	0.27
Property Plant Equipment	0.8	-0.54	0.68	-0.29	-0.93	0.89	0.74	0.89	0.81	0.97	0.96	-0.74	-0.32	-0.47	0.51		0.95	0.42	0.0	-0.71	0.85	0.75
Capital Stock	0.83	-0.5	0.57	-0.36	-0.95	0.84	0.68	0.89	0.84	0.96	0.99	-0.65	-0.41	-0.42	0.56	0.95		0.41	-0.16	-0.73	0.82	0.76
Short Term Debt	0.7	0.32	0.03	-0.86	-0.3	0.24	0.13	0.29	0.68	0.39	0.42	0.13	0.11	0.43	0.73	0.42	0.41		0.59	0.08	-0.01	-0.17
Long Term Debt	0.04	0.41	-0.28	-0.39	0.23	-0.08	-0.25	-0.28	0.03	-0.07	-0.09	0.33	0.7	0.43	0.13	0.0	-0.16	0.59		0.43	-0.3	-0.48
Long Term Investments	-0.45	0.9	-0.82	-0.15	0.86	-0.8	-0.49	-0.89	-0.49	-0.72	-0.69	0.75	0.72	0.83	-0.26	-0.71	-0.73	0.08	0.43		-0.87	-0.91
Short Long Term Debt	0.61	-0.76	0.82	0.03	-0.89	0.91	0.8	0.88	0.63	0.86	0.82	-0.76	-0.43	-0.67	0.37	0.85	0.82	-0.01	-0.3	-0.87		0.97
Deferred Long Term Liab	0.49	-0.81	0.78	0.15	-0.84	0.85	0.71	0.84	0.52	0.78	0.75	-0.75	-0.54	-0.73	0.27	0.75	0.76	-0.17	-0.48	-0.91	0.97

Click cells to compare fundamentals

About ADC Therapeutics Financial Statements

ADC Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	77.1 M	80.9 M
Gross Profit Margin	0.87	0.91

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC